SEC Form SC 13G filed by Cyclacel Pharmaceuticals Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
| Cyclacel Pharmaceuticals, Inc. |
|
(Name of Issuer) |
| Common Stock, par value $0.001 per share |
| (Title of Class of Securities) |
|
23254L801 |
|
(CUSIP Number) |
| December 21, 2023 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) | |
| ☒ | Rule 13d-1(c) | |
| ☐ | Rule 13d-1(d) |
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Page 2 of 9
| CUSIP No. | 23254L801 |
| 1 |
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS |
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY | |||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, United States of America |
|||
|
NUMBER OF BENEFICIALLY EACH PERSON |
5 |
SOLE VOTING 0 |
||
| 6 |
SHARED VOTING POWER 82,032 shares of Common Stock 194,100 shares of Common Stock issuable upon exercise of 2023 Warrants(1) 109,850 shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1) 30,000 shares of Common Stock issuable upon exercise of Warrants(1) |
|||
| 7 |
SOLE DISPOSITIVE POWER 0 |
|||
| 8 |
SHARED DISPOSITIVE POWER 82,032 shares of Common Stock 194,100 shares of Common Stock issuable upon exercise of 2023 Warrants(1) 109,850 shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1) 30,000 shares of Common Stock issuable upon exercise of Warrants(1) |
|||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 82,032 shares of Common Stock 194,100 shares of Common Stock issuable upon exercise of 2023 Warrants(1) 109,850 shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1) 30,000 shares of Common Stock issuable upon exercise of Warrants(1) |
|||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES | ☐ | ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.0%(1)(2) |
|||
| 12 |
TYPE OF REPORTING PERSON IA, PN |
|||
| (1) | As more fully described in Item 4, 2023 Warrants, the Prefunded Warrants, and Warrants (collectively the “Reported Warrants”) are each subject to a 4.99% blocker (the “Warrant Blockers”). The percentage set forth in Row 11 for each Reporting Person gives effect to the Warrant Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able exercise the Reported Warrants to the extent that in the aggregate the Fund would receive shares of more than 4.99% of Common Stock of the Issuer. |
| (2) | Based on 1,019,310 shares of Common Stock outstanding as reported in the Issuers Form 424(b)(5) dated December 21, 2023, and filed with the Securities and Exchange Commission on December 26, 2023. |
Page 3 of 9
| CUSIP No. | 23254L801 |
| 1 |
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS |
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY | |||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, United States of America |
|||
|
NUMBER OF BENEFICIALLY EACH PERSON |
5 |
SOLE VOTING 0 |
||
| 6 |
SHARED VOTING POWER 82,032 shares of Common Stock 194,100 shares of Common Stock issuable upon exercise of 2023 Warrants(1) 109,850 shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1) 30,000 shares of Common Stock issuable upon exercise of Warrants(1) |
|||
| 7 |
SOLE DISPOSITIVE POWER 0 |
|||
| 8 |
SHARED DISPOSITIVE POWER 82,032 shares of Common Stock 194,100 shares of Common Stock issuable upon exercise of 2023 Warrants(1) 109,850 shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1) 30,000 shares of Common Stock issuable upon exercise of Warrants(1) |
|||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 82,032 shares of Common Stock 194,100 shares of Common Stock issuable upon exercise of 2023 Warrants(1) 109,850 shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1) 30,000 shares of Common Stock issuable upon exercise of Warrants(1) |
|||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES | ☐ | ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.0%(1)(2) |
|||
| 12 |
TYPE OF REPORTING PERSON PN |
|||
| (1) | As more fully described in Item 4, 2023 Warrants, the Prefunded Warrants, and Warrants (collectively the “Reported Warrants”) are each subject to a 4.99% blocker (the “Warrant Blockers”). The percentage set forth in Row 11 for each Reporting Person gives effect to the Warrant Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able exercise the Reported Warrants to the extent that in the aggregate the Fund would receive shares of more than 4.99% of Common Stock of the Issuer. |
| (2) | Based on 1,019,310 shares of Common Stock outstanding as reported in the Issuers Form 424(b)(5) dated December 21, 2023, and filed with the Securities and Exchange Commission on December 26, 2023. |
Page 4 of 9
| CUSIP No. | 23254L801 |
| 1 |
NAME OF REPORTING PERSONS Altium Growth GP, LLC
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS |
|||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ☐ (b) ☐ | ||
| 3 | SEC USE ONLY | |||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, United States of America |
|||
|
NUMBER OF BENEFICIALLY EACH PERSON |
5 |
SOLE VOTING 0 |
||
| 6 |
SHARED VOTING POWER 82,032 shares of Common Stock 194,100 shares of Common Stock issuable upon exercise of 2023 Warrants(1) 109,850 shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1) 30,000 shares of Common Stock issuable upon exercise of Warrants(1) |
|||
| 7 |
SOLE DISPOSITIVE POWER 0 |
|||
| 8 |
SHARED DISPOSITIVE POWER 82,032 shares of Common Stock 194,100 shares of Common Stock issuable upon exercise of 2023 Warrants(1) 109,850 shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1) 30,000 shares of Common Stock issuable upon exercise of Warrants(1) |
|||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 82,032 shares of Common Stock 194,100 shares of Common Stock issuable upon exercise of 2023 Warrants(1) 109,850 shares of Common Stock issuable upon exercise of Pre-Funded Warrants(1) 30,000 shares of Common Stock issuable upon exercise of Warrants(1) |
|||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES | ☐ | ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.0%(1)(2) |
|||
| 12 |
TYPE OF REPORTING PERSON OO |
|||
| (1) | As more fully described in Item 4, 2023 Warrants, the Prefunded Warrants, and Warrants (collectively the “Reported Warrants”) are each subject to a 4.99% blocker (the “Warrant Blockers”). The percentage set forth in Row 11 for each Reporting Person gives effect to the Warrant Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able exercise the Reported Warrants to the extent that in the aggregate the Fund would receive shares of more than 4.99% of Common Stock of the Issuer. |
| (2) | Based on 1,019,310 shares of Common Stock outstanding as reported in the Issuers Form 424(b)(5) dated December 21, 2023, and filed with the Securities and Exchange Commission on December 26, 2023. |
Page 5 of 9
| CUSIP No. | 23254L801 |
| Item 1(a). | Name of Issuer: | Cyclacel Pharmaceuticals, Inc.. (the “Issuer”) | |
| Item 1(b). |
Address of Issuer’s Principal Executive Offices: |
200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 |
| Item 2(a). |
Name of Person Filing: This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities, owned by the Fund.
Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.
Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer. | ||
| Item 2(b). | Address of Principal Business Office or, if None, Residence: | ||
| The address of the principal business office of each of the reporting persons is 152 West 57th Street, FL 20, New York, NY 10019 | |||
| Item 2(c). | Citizenship: | ||
| See Item 4 on the cover page(s) hereto. | |||
| Item 2(d). | Title of Class of Securities: | ||
| Common Stock, par value $0.001 per share (“Common Stock”) | |||
| Item 2(e). | CUSIP Number: 23254L801 | ||
| Item 3. | If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a: | ||
| (a) | ☐ | Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). | |
| (b) | ☐ | Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). | |
Page 6 of 9
| CUSIP No. | 23254L801 |
| (c) | ☐ | Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). | |
| (d) | ☐ | Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). | |
| (e) | ☐ | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); | |
| (f) | ☐ | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); | |
| (g) | ☐ | A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G); | |
| (h) | ☐ | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | |
| (i) | ☐ | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); | |
| (j) | ☐ | Group, in accordance with §240.13d-1(b)(1)(ii)(J). | |
| Item 4. | Ownership. | ||
|
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 1,019,310 shares of Common Stock outstanding as reported in the Issuers Form 424(b)(5) dated December 21, 2023, and filed with the Securities and Exchange Commission on December 26, 2023.
Pursuant to the terms of the securities purchase agreement entered into between the Fund and the Issuer, the Fund purchased Common Stock, 2023 Warrants, Prefunded Warrants, and Warrants (collectively the “Reported Warrants”). The Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the “Warrant Blockers”).
The percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Warrant Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able exercise the Reported Warrants to the extent that in the aggregate the Fund would receive shares of more than 4.99% of Common Stock of the Issuer. | |||
Page 7 of 9
| CUSIP No. | 23254L801 |
| Item 5. | Ownership of Five Percent or Less of a Class. |
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ] | |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
| Not applicable | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
| Not applicable | |
| Item 8. | Identification and Classification of Members of the Group. |
| Not applicable | |
| Item 9. | Notice of Dissolution of Group. |
| Not applicable | |
| Item 10. | Certification. |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Dated: | January 9, 2024 | |
| Altium Capital Management, LP | ||
| By: | /s/ Jacob Gottlieb | |
| Name: | Jacob Gottlieb | |
| Title: | CEO | |
|
Altium Growth Fund, LP
By: Altium Growth GP, LLC Its: General Partner
|
||
| Signature: | /s/ Jacob Gottlieb | |
| Name: | Jacob Gottlieb | |
| Title: | Managing Member of Altium Growth GP, LLC | |
| Altium Growth GP, LLC | ||
| By: | /s/ Jacob Gottlieb | |
| Name: | Jacob Gottlieb | |
| Title: | Managing Member | |
Page 8 of 9
EXHIBIT INDEX
EXHIBIT 1: Joint Acquisition Statement Pursuant to Section 240.13d-1(k)